Pharmaceuticals in Europe

Pharmaceuticals in Europe

  • June 2017
  • 36 pages
  • MarketLine
Report ID: 188774
Pharmaceuticals in Europe

Summary

Pharmaceuticals in Europe industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Europe pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Findings

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
- The European pharmaceuticals market had total revenues of $208.9bn in 2016, representing a compound annual growth rate (CAGR) of 3.6% between 2012 and 2016.
- Forecasted growth in the coming years is dependent on emerging economies such as Turkey, the pharmaceutical market in which has been subject of attention from Japanese companies.
- The European market is mainly made up of very mature markets which are slow to produce growth and have domestic government policy aimed at reducing pharmaceutical expenditure.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Europe
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Europe
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Europe pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Europe pharmaceuticals market by value in 2016?
- What will be the size of the Europe pharmaceuticals market in 2021?
- What factors are affecting the strength of competition in the Europe pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Europe’s pharmaceuticals market?
Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Johnson & Johnson
Novartis AG
Pfizer Inc.
Sanofi SA
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: Europe pharmaceuticals market value: $ billion, 2012–16
Table 2: Europe pharmaceuticals market geography segmentation: $ billion, 2016
Table 3: Europe pharmaceuticals market share: % share, by value, 2016
Table 4: Europe pharmaceuticals market value forecast: $ billion, 2016–21
Table 5: Johnson & Johnson: key facts
Table 6: Johnson & Johnson: key financials ($)
Table 7: Johnson & Johnson: key financial ratios
Table 8: Novartis AG: key facts
Table 9: Novartis AG: key financials ($)
Table 10: Novartis AG: key financial ratios
Table 11: Pfizer Inc.: key facts
Table 12: Pfizer Inc.: key financials ($)
Table 13: Pfizer Inc.: key financial ratios
Table 14: Sanofi SA: key facts
Table 15: Sanofi SA: key financials ($)
Table 16: Sanofi SA: key financials (€)
Table 17: Sanofi SA: key financial ratios

List of Figures
Figure 1: Europe pharmaceuticals market value: $ billion, 2012–16
Figure 2: Europe pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 3: Europe pharmaceuticals market share: % share, by value, 2016
Figure 4: Europe pharmaceuticals market value forecast: $ billion, 2016–21
Figure 5: Forces driving competition in the pharmaceuticals market in Europe, 2016
Figure 6: Drivers of buyer power in the pharmaceuticals market in Europe, 2016
Figure 7: Drivers of supplier power in the pharmaceuticals market in Europe, 2016
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Europe, 2016
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Europe, 2016
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Europe, 2016
Figure 11: Johnson & Johnson: revenues & profitability
Figure 12: Johnson & Johnson: assets & liabilities
Figure 13: Novartis AG: revenues & profitability
Figure 14: Novartis AG: assets & liabilities
Figure 15: Pfizer Inc.: revenues & profitability
Figure 16: Pfizer Inc.: assets & liabilities
Figure 17: Sanofi SA: revenues & profitability
Figure 18: Sanofi SA: assets & liabilities
Country=Europe Industry=Pharmaceutical ParentIndustry=Pharmaceutical Date=201706 Topic=MarketReport Publisher=MarketLine Price=1000